2017 American Transplant Congress
Clinical Outcomes of Simplified Once-Daily Immunosuppressive Regimen for Stable Kidney Recipients.
Aims. Many immunosuppressive drugs are prescribed as twice-daily dosing. Simplified once-daily dosing of the entire drug regimen can improve treatment satisfaction for patients. We examined…2017 American Transplant Congress
Effect of Everolimus on the Cardiac Function in Kidney Transplant Recipients.
PURPOSE: In this study, we evaluated the effect of everolimus (EVR), one of the mammalian targets of rapamycin on cardiac function in kidney transplant recipients.METHODS:We…2017 American Transplant Congress
The Efficacy and Safety of Plaquenil in Kidney Transplants Patients with Lupus.
Background: Hydroxychloroquine, also known as Plaquenil ( PLQ) is an antimalarial drug with immunomodulatory action. Recent studies have demonstrated a protective effect of PLQ in…2017 American Transplant Congress
Efficacy of Calcineurin Inhibitors Transferring to Rapamycin in Live Kidney Transplantation from Old Donors to Young Recipients.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Background Calcineurin inhibitor(CNI) nephrotoxicity is one of the major reasons for chronic allograft injury in live kidney transplantation from old donors to young recipients. Therefore…2017 American Transplant Congress
Influence of Tacrolimus Metabolism Rate on Patients' Survival After Renal Transplantation.
Introduction: Tacrolimus (Tac) is an integral part of the immunosuppressive regimen after renal transplantation (RTx). A fast Tac metabolism rate defined as the Tac blood…2017 American Transplant Congress
Tacrolimus Dose Requirement Based on the CYP3A5 Genotype in Renal Transplant Patients.
Background The aim of the present study is to determine whether CYP3A5*A and CYP3A5*G genotype is a predictive index of tacrolimus dose requirement, and also…2017 American Transplant Congress
Evaluation of the Conversion from Brand Name to Generic Immunosuppression in Hospitalized Organ Transplant Recipients.
Purpose: Safe and effective immunosuppressant medications are critical to accomplish good graft and patient survival rates. The availability of “AB-rated” generic immunosuppression affords the opportunity…2017 American Transplant Congress
Risks Associated with Recombinant IL2 Therapy in Renal Transplantation.
Brigham and Women's Hospital, Boston
Regulatory T cells are critical to allograft survival. We report a pilot study of safety and tolerability of low dose recombinant IL2 (rIL2), 1x106 units/m2/day…2017 American Transplant Congress
Early Exposure of Everolimus with and without Calcineurin Inhibitors.
Nephrology Division, Hospital do Rim, UNIFESP, São Paulo, SP, Brazil
This study aimed to evaluate the effect of cyclosporine (CSA) or tacrolimus (TAC) on early exposure of everolimus (EVR).A cohort of 306 kidney transplant recipients…2017 American Transplant Congress
Is Once-Daily Extended-Release Tacrolimus Better Than Twice-Daily Standard-Release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials.
Tacrolimus is one of the major immunosuppressants commonly used in transplant recipients. Extended-release tacrolimus is expected to have immunosuppressant effects equivalent to standard-release tacrolimus while…
American Transplant Congress abstracts